Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new measures to improve how the risks of suicidal thoughts and behaviors and persistent sexual dysfunction are communicated to people taking antidepressants.

Following a review involving patients and their families, the MHRA will introduce a boxed warning in patient information leaflets (PILs), a patient safety card, and an additional safety leaflet. The term “post-SSRI sexual dysfunction” (PSSD) will also be added to the leaflets for certain antidepressants.

“Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions,” Dr. Alison Cave, MHRA chief safety officer, said.

She said the changes would support informed discussions among patients, caregivers, and healthcare professionals. Dr. Cave added that antidepressants can effectively treat depression when used appropriately and under clinical supervision. Patients should not stop taking these medicines without first consulting their healthcare professional.

What Are the New Antidepressant Warnings?

Also read: GLP-1 Drugs May Offer Mental Health Benefits, Reduce Schizophrenia Relapses: Lancet Study

Patient information leaflets will feature a boxed warning directing readers to information about suicidal thoughts and behaviors, making the guidance easier to find.

A patient safety card is expected to accompany medicine packaging, reinforcing key safety messages and explaining when and how to seek support.

For certain antidepressants, updated leaflets will include information on PSSD, highlighting the possibility that sexual dysfunction may persist after treatment ends.

The MHRA is also developing an additional safety leaflet with the wider healthcare system. Expected in 2027, it will explain the benefits and risks of antidepressant treatment to support informed decisions. It will be given to patients at their first appointment discussing antidepressants and to those already receiving treatment.

Concerns Over SSRI Safety Warnings

The MHRA has received four prevention of future deaths reports since 2020 concerning antidepressant prescribing and safety information. One followed the 2024 death by suicide of Thomas Kingston, husband of Lady Gabriella Kingston, at age 45.

An inquest heard that Kingston had been prescribed sertraline and later switched to citalopram after reporting that his medication was not helping. Both are selective serotonin reuptake inhibitors (SSRIs). He had also received the sleeping tablet zopiclone for sleep difficulties and had stopped taking his medication before his death.

Gloucestershire senior coroner Katy Skerrett questioned whether patients were adequately informed about the suicide risks associated with SSRIs. Kingston’s parents called for clearer communication of potential side effects to patients and their families.

Read More: AI Chatbots May Be Changing How Children Seek Emotional Support

What Should Healthcare Professionals Do?

The MHRA advises healthcare professionals to:

• Discuss the risk of suicidal thoughts and behaviors when starting antidepressants, changing doses, and during subsequent reviews.
• Explain that some antidepressants can cause sexual dysfunction that may continue after treatment stops.
• Follow relevant National Institute for Health and Care Excellence (NICE) guidance and monitor patients regularly after treatment begins.
• Provide the additional safety leaflet when it becomes available in 2027.
• Report suspected adverse reactions through the MHRA’s Yellow Card scheme.

What Should Patients Taking Antidepressants Know?

Patients experiencing new or worsening suicidal thoughts should seek urgent medical attention, particularly when starting treatment or changing their dose. In the UK, they can contact NHS 111, their local mental health crisis team, Samaritans on 116 123, or the SHOUT text service at 85258.

Anyone concerned about sexual dysfunction during or after antidepressant treatment should contact their healthcare professional.

The MHRA said these are not new risks associated with the medicines. Patients should read the information supplied with their medication and consult their healthcare professional before stopping treatment.

Lead poisoning is a widespread but preventable health threat that contributes to more than 3.5 million deaths globally each year and puts hundreds of millions of children at risk, the World Health Organization (WHO) said.

Marking International Lead Poisoning Prevention Week 2026, WHO urged countries to accelerate prevention efforts amid growing global momentum to tackle lead exposure.

Why Is Lead Dangerous for Children?

Also read: Lead Found In Everyday Vegetables - Reveals A Bengaluru Study

Children are particularly vulnerable to lead because their developing brains and nervous systems are highly susceptible to its toxic effects. Even low levels of exposure can cause irreversible harm, affecting learning, behavior and development.

“Lead poisoning should not be stealing children's potential in 2026,” said Bruce Gordon, Director a.i. of WHO’s Department of Environment, Climate Change, One Health and Migration.

“We know where many exposures come from and we know how to prevent them. Countries now need to move upstream, removing lead from products and environments before it reaches a child's bloodstream. WHO is working with governments and partners to help turn that evidence into action,” Gordon added.

How Does Lead Poisoning Occur?

There is no known safe level of lead exposure, WHO warned. Exposure can occur through paint, cookware, cosmetics, spices, informal recycling and industrial contamination, among other sources.

Lead affects multiple organs and can contribute to cardiovascular and kidney disease in adults. In children, exposure can cause lasting damage to brain function and development. Its effects may go undetected until significant harm has occurred.

Lead is distributed to the brain, liver, kidney and bones. It is stored in the teeth and bones, where it can accumulate over time. Human exposure is assessed through the measurement of lead in blood.

WHO Plans Global Action On Lead Exposure

Fewer than half of countries had confirmed legally binding controls on lead paint, according to WHO's latest published global assessment.

This year's International Lead Poisoning Prevention Week theme, “From Detection to Prevention,” highlights the need for stronger policies, better enforcement of safety standards and greater public awareness to eliminate lead hazards at their source.

WHO Member States have recognized lead exposure as a pressing public health concern and mandated the development of a Global Action Plan on Lead Mitigation, which will be presented to the World Health Assembly in 2027.

The WHO will also launch the PREVENT Technical Package on Lead Poisoning Prevention in 2027. It will provide practical guidance to help countries identify major exposure sources, prioritize interventions, strengthen regulations and track progress.

Last year, WHO joined partners in the Lead Poisoning Prevention Initiative to strengthen laboratory capacity for blood lead testing, supporting the monitoring and early detection of exposure.

The initiative will provide technical support and build laboratory capacity in Brazil, five states in India, Nepal and six sub-Saharan African countries: Ethiopia, Ghana, Malawi, Rwanda, South Africa and the United Republic of Tanzania.

WHO Calls for Stronger Prevention Measures

Preventing lead exposure can also reduce health care costs, improve educational outcomes and support healthier, more productive societies.

The WHO urged countries to move beyond detecting lead exposure and adopt comprehensive prevention strategies such as:

• Eliminating lead hazards from products and environments.
• Strengthening regulations and enforcement.
• Improving monitoring and surveillance of lead exposure.
• Strengthening capacity to manage lead poisoning cases.
• Raising public awareness about exposure sources and prevention.
• Promoting safer industrial practices and waste management.
• Prioritizing children and other vulnerable populations.

Scottish swimmer Archie Goodburn has welcomed the UK government’s plans to review progress in brain cancer research after years of campaigning for better treatment and greater investment in research.

Goodburn, 25, revealed in 2024 that he had been diagnosed with three inoperable brain tumors. In August, he broke down during an interview on BBC Breakfast as he spoke about the challenges faced by patients with brain cancer and their families.

He appealed to the government to invest more in research, urging it to “give us a chance to fight for our lives.” His plea led to a meeting with Prime Minister Andy Burnham.

The government has now announced a new national brain cancer clinical lead and a review of progress in brain cancer research, with the aim of helping patients access treatments sooner, the BBC reported.

Goodburn thanked the prime minister, saying all three of his requests had been “promised to some extent,” although the details still needed to be worked out.

Burnham described Goodburn as an “inspiration to us all” and said he was “delighted” to welcome him to Downing Street.

“He has spoken passionately about the need for change on brain cancer, and he's right: progress hasn't been good enough, here or anywhere else. Families facing this disease can't afford to wait,” Burnham said.

How Will the Brain Cancer Review Work?

Also read: 'Give Us a Chance to Fight': Archie Goodburn Makes Emotional Appeal For Better Brain Cancer Research; UK PM Responds

According to the BBC, the review will be led by Professor Anthony Chalmers, chair of clinical oncology at the University of Glasgow. It will assess progress in brain cancer research since 2018 and identify “what is still holding progress back.”

The review will be followed by a national cancer plan aimed at getting new treatments “out of the lab and to patients faster,” Downing Street said.

The prime minister has also asked the Medicines and Healthcare products Regulatory Agency (MHRA) to complete its review of regulations for medicines used to treat rare conditions sooner.

Goodburn has urged the regulator to finish the review within two years rather than three, bringing forward potential changes that could help patients access new treatments sooner.

Scotland Pledges Support for Brain Cancer Care

Read More: Saba Ali Khan Opens Up About Brain Tumour: Can It Go Unnoticed If You Walk, Talk And Work Normally?

Scottish First Minister John Swinney, who also recently met Goodburn, highlighted the Scottish government's commitment to supporting more clinical trials.

“We are proud to support national leadership for brain cancer through the Scottish Adult Neuro-Oncology Network,” Swinney said.

The network brings together clinicians, patients and voluntary sector representatives to improve care for people with brain cancer across Scotland.

“We will give careful consideration to any further role which Scotland could play to give people living with brain cancer a faster route from research to treatment,” he added.

Archie Goodburn's Brain Cancer Diagnosis

READ: Survival In Aggressive Brain Tumors Improves By Up To 50% in India, Say Doctors

The Edinburgh-born swimmer sought medical tests after experiencing numbness and seizures while training for the 2024 Olympic trials. He was diagnosed with three large oligodendrogliomas, a rare type of tumor that can affect the brain and spinal cord.

He underwent chemotherapy and radiotherapy, but surgery to remove the tumors was not possible.

Despite his diagnosis, Goodburn competed at the 2026 Commonwealth Games in Glasgow, reaching the final of the 50-meter breaststroke but narrowly missing out on a medal.

Charity Brain Tumour Research has described brain tumors as the cancer most likely to kill people under 40 in the UK.

“One of my dreams is that we see a future where brain cancer isn't the biggest killer of patients under 40,” Goodburn said during the Commonwealth Games.